Merit Medical Systems (NASDAQ:MMSI) Stock Price Target Raised at BTIG Research

Merit Medical Systems (NASDAQ:MMSI) had its target price upped by BTIG Research from $105.00 to $110.00 in a research note issued to investors on Friday,Benzinga reports. The brokerage currently has a buy rating on the medical instruments supplier’s stock.

A number of other brokerages also recently issued reports on MMSI. Barrington Research set a $114.00 price target on Merit Medical Systems in a report on Friday, July 31st. Wells Fargo & Company lifted their target price on Merit Medical Systems from $74.00 to $83.00 and gave the stock an “equal weight” rating in a research report on Friday, July 31st. Needham & Company LLC raised their target price on shares of Merit Medical Systems from $101.00 to $106.00 and gave the stock a “buy” rating in a research report on Friday. Raymond James Financial reaffirmed an “outperform” rating and issued a $100.00 target price on shares of Merit Medical Systems in a report on Friday, July 31st. Finally, Piper Sandler upped their price objective on Merit Medical Systems from $96.00 to $106.00 and gave the company an “overweight” rating in a research note on Friday, July 31st. Eight investment analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Merit Medical Systems presently has a consensus rating of “Moderate Buy” and an average price target of $105.55.

Merit Medical Systems Stock Down 7.7%

Shares of NASDAQ MMSI opened at $86.24 on Friday. The stock has a market cap of $5.15 billion, a P/E ratio of 32.42, a PEG ratio of 2.33 and a beta of 0.51. The company has a current ratio of 4.20, a quick ratio of 2.79 and a debt-to-equity ratio of 0.44. Merit Medical Systems has a 12-month low of $59.74 and a 12-month high of $94.85. The business’s fifty day simple moving average is $88.60 and its 200-day simple moving average is $77.14.

Merit Medical Systems (NASDAQ:MMSI) last posted its quarterly earnings results on Thursday, October 29th. The medical instruments supplier reported $1.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.04 by $0.08. The company had revenue of $416.24 million for the quarter, compared to analyst estimates of $410.56 million. Merit Medical Systems had a return on equity of 14.37% and a net margin of 9.94%. Merit Medical Systems’s revenue for the quarter was up 8.4% compared to the same quarter last year. During the same quarter last year, the company earned $0.92 EPS. As a group, equities analysts predict that Merit Medical Systems will post 3.84 EPS for the current fiscal year.

Hedge Funds Weigh In On Merit Medical Systems

Several hedge funds have recently added to or reduced their stakes in MMSI. Kilter Group LLC acquired a new stake in shares of Merit Medical Systems during the 2nd quarter worth about $25,000. Salomon & Ludwin LLC lifted its position in Merit Medical Systems by 140.8% during the third quarter. Salomon & Ludwin LLC now owns 537 shares of the medical instruments supplier’s stock worth $46,000 after buying an additional 314 shares during the period. IFP Advisors Inc boosted its stake in Merit Medical Systems by 88.6% in the 3rd quarter. IFP Advisors Inc now owns 694 shares of the medical instruments supplier’s stock worth $60,000 after buying an additional 326 shares during the last quarter. Harbor Investment Advisory LLC purchased a new stake in Merit Medical Systems in the 2nd quarter valued at about $50,000. Finally, Pinnacle Wealth Planning Services Inc. increased its stake in shares of Merit Medical Systems by 84.0% during the 3rd quarter. Pinnacle Wealth Planning Services Inc. now owns 784 shares of the medical instruments supplier’s stock valued at $68,000 after acquiring an additional 358 shares during the last quarter. 99.66% of the stock is currently owned by hedge funds and other institutional investors.

Merit Medical Systems News Summary

Here are the key news stories impacting Merit Medical Systems this week:

• Positive Sentiment: Strong Q3 earnings beat expectations. Merit reported third-quarter revenue of $416.2 million, up 8.4% year over year and ahead of the $410.6 million consensus estimate. Non-GAAP EPS was $1.12 versus expectations of $1.04, while GAAP EPS rose 51% to $0.70. Merit Medical Q3 2026 results
• Positive Sentiment: Profitability and cash generation improved. Organic constant-currency revenue increased 9%, GAAP operating margin expanded to 14.1% from 11.1%, and year-to-date operating cash flow reached $175.2 million, with $129.5 million in free cash flow.
• Positive Sentiment: Full-year guidance was raised. Management increased its 2026 earnings outlook following the strong quarter, supporting expectations for continued growth. Merit Medical raises 2026 guidance
• Positive Sentiment: Analysts raised targets. BTIG Research lifted its target from $105 to $110 and maintained a buy rating. Wells Fargo raised its target from $83 to $92, although it retained an equal-weight rating. Analysts raise Merit Medical price targets
• Positive Sentiment: Cardiac-therapy capabilities expanded. Merit acquired Solo Pace, adding temporary pacing technology designed for patients with aortic stenosis and strengthening its TAVR-related product portfolio. Merit Medical acquires Solo Pace
• Neutral Sentiment: Valuation remains a consideration. With the stock trading at roughly 36 times earnings and near its 52-week high, investors may be demanding continued execution, leaving limited room for disappointment.
• Negative Sentiment: Some caution remains among analysts. Wells Fargo’s equal-weight rating and the company’s narrowed sales outlook temper the bullish impact of the earnings beat and guidance increase.

About Merit Medical Systems

Merit Medical Systems, Inc is a medical device company that develops, manufactures and distributes disposable products used in interventional, diagnostic and therapeutic procedures. Its devices are designed for use by healthcare professionals in hospitals, outpatient facilities and other clinical settings.

The company’s product portfolio includes devices for vascular access, angiography, intervention, drainage, embolization, oncology and cardiac procedures. Merit also offers products used in peripheral intervention, spine procedures and other specialized areas of minimally invasive medicine, including kits, accessories and related procedural equipment.

Founded in 1987 and headquartered in South Jordan, Utah, Merit Medical serves healthcare providers through a global commercial and manufacturing network.